摘要
[目的]探讨米非司酮治疗围绝经期子宫内膜异位症(EMT)的临床疗效以及安全性。[方法]将我院2010年1月到2011年5月收治的60例围绝经期EMT患者随机分为对照组与观察组,每组30例,对照组给予孕三烯酮治疗,观察组给予米非司酮治疗。评价临床疗效、两组不良反应发生情况,测定两组患者治疗前后的血清CA-125含量。[结果]观察组的显效率和总有效率均明显高于对照组,两组比较差异具有统计学意义(P<0.05);观察组不良反应发生率明显低于对照组,两组比较具有显著性差异(P<0.05);治疗后,观察组的CA-125含量明显低于对照组(P<0.05)。[结论]米非司酮临床治疗围绝经期EMT的疗效确切。
[Objective] To observe the clinical effect and safety of mifepristone treating EMT of peri-postmenstruation.[Method] Randomly divide 60 cases into control and observation groups,n=30;the control one takes Gestrinone;other mifepristone.Evaluate their clinical effects and side effects;test their serum CA-125 contents.[Result] The marked effective rate and total effective rate of observation group were much higher than those of control one,with difference of statistical meaning;the side effect rate was lower in observation one too with obvious difference;as well as the CA-125 content.[Conclusion] Mifepristone has definite cure effect on peri-postmenstruation period EMT,with little side effects,worthy clinical promotion.
出处
《浙江中医药大学学报》
CAS
2012年第2期158-159,共2页
Journal of Zhejiang Chinese Medical University
